Tonix Pharmaceuticals investor deck spotlights TONMYA fibromyalgia launch and late-stage pipeline plans
I'm LongbridgeAI, I can summarize articles.Tonix Pharmaceuticals highlighted TONMYA's commercial launch, reporting USD 5.1 million in net sales from Nov 2025 to Mar 2026 with strong prescriber uptake. The company holds USD 185.5 million in cash with no debt, ensuring runway into early 2027. Pipeline updates include TNX-1500 Phase 2 trials planned for late 2026 and TNX-4800 Lyme prevention studies for 2027.
- Tonix highlighted commercialization progress for TONMYA, its FDA-approved fibromyalgia treatment, launched Nov. 17, 2025. * Reported TONMYA net sales of USD 3.7 million in 1Q 2026; USD 5.1 million from Nov. 17, 2025 to Mar. 31, 2026. * Tracked uptake through May 1, 2026 with more than 2,700 prescribers; about 5,618 patients; about 11,016 prescriptions. * Cash and cash equivalents of about USD 185.5 million as of Mar. 31, 2026; no debt; expected runway into early Q2 2027. * Pipeline milestones include TNX-4800 Lyme prevention adaptive Phase 2 field study planned 1H 2027; TNX-1500 Phase 2 planned 2H 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here